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ABSTRACT 
The current review on in situ gelling systems becomes one of the most popular and prominent. It had a tremendous potential advantage of delivery 
systems due to many benefits like easy to use simple manufacturing; improve both adherence and patient comfort by minimizing the frequency of 
drug administration by its unique characteristics feature of sol to gel transition. It also provides in situ gelling nanoemulsions, nanosphere, 
microspheres, and liposomes. The drawbacks associated with conventional systems of both solutions and gels, such as accurate dosing, ease of 
administration overcome by using in situ gelling systems. This review focused on definitions, types, advantages, disadvantages, polymers used, and 
suitable characteristics of polymers, including the preparation of in situ gels covered in the introduction. Approaches, applications, and evaluation 
of in situ gels were explained with examples.  
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INTRODUCTION 
A gel is a soft, stable, or solid-like material which consists of at least 
two components, one of them being a liquid, present in substantial 
quantity [1]. Gels are a transitional state of matter containing both 
liquid and reliable ingredients (semisolids or semi-liquids). Gels 
combine the cohesive properties of solids and the diffusive transport 
characteristics of fluids [2]. It consists of a three-dimensional, stable, 
and secure component network [3]. In gels, the polymer network is 
formed by the cross-linking of polymer chains either by the 
formation of covalent (chemical cross-linking) or non-covalent 
bonds (physical cross-linking). Based on nature, gels are classified 
into two types (i.e., physical and chemical). Physical gels have weak 
bonds like hydrogen, electrostatic, and Vander Waal bonds [4]. Due 
to toxicity concern, there is increasing interest in physically cross-
linked gels—chemical gels when arising strong covalent bonds [5]. 
Hydrogels are the polymeric chains of three-dimensional (3-D) 
structures. So, they can be easily forms in various sizes and shapes 
[6]. These hydrogels have an excellent absorbing ability to transition 
between liquid-gel and itself; it is a type of hydrophilic preparations 
[7]. Hydro-gels consist of cross-links to serve to accommodate a 
considerable amount of air, and it retains enormous amounts of 
water and biological fluids to swell. Hydrogels are also classified into 
two types (i.e., preformed hydrogels and in situ gels) [8]. 
Preformed gels or preformed particle gels (PPG) are simple viscous 
solutions that can’t undergo any modification after administration 
[9]. PPG is superabsorbent cross-linking polymers that can swell up 
to 200 times its original size and act as a fluid diverting agent to 
control conformance is a novel process designed to overcome some 
distinct drawbacks inherent in situ gelation system [10]. To 
overcome changes in gel composition, degradation, lack of gelation 
time control, and several weaknesses go with preformed gels. Still, 
dilution by water and it has a defect in ophthalmic dosage form, 
including less accurate dose, blurred vision, lacrimation, etc. 
preformed gels are formed on the surface before it is injecting 
through the reservoir [11]. Hence, no gelation occurs, and it needs to 
be considered, including pH, salinity, multivalent ions, hydrogen 
sulfide, temperature, and shear rate [10]. 
In situ gels are the solutions or suspensions that undergo gelation 
after reaching the particular site due to contact with body fluids or 
physicochemical changes such as pH, temperature, ionic 
concentration, UV radiation, presence of specific molecules, or ions, 
external triggers, etc. [12]. In situ gel produces a constant plasma 
drug profile in the body by extending the release of a drug, so it is 
attached and absorbed in gel form and is known to prolong the life of 
the drug in the mucosa [13]. The drug delivery systems having the 
properties, as mentioned earlier, of sol to gel transition can be 
widely used for sustained delivery vehicle preparation of bioactive 
molecules [14]. In situ gels, potentially used for oral, buccal, 
subcutaneous, transdermal, intraperitoneal, ocular, nasal, rectal, 
vaginal, and parenteral routes [15]. From a manufacturing point of 
view, less complicated and thus lowers the investment and 
manufacturing cost [16]. In the discovery phase, the gel formulations 
are used to enhance the local and systemic exposure of potential 
lead compounds, which is ideal for establishing animal models for 
various conditions quickly and cost-effective [17]. Despite the 
massive diversity of gels, a particular class of gels, namely smart 
polymer gels, are in the focus of pharmaceutical research during the 
last decades [18]. These intelligent polymers change their 
physicochemical properties in response to an altered environment. 
In recent advances, in situ gels have made it possible to exploit the 
changes in physiological uniqueness [19]. Comprehensive research 
has been carried in designing of in situ gels, emerged as one of the 
best novel drug delivery systems (NDDS) [20]. In this review, they 
mainly focussed on introduction, advantages, disadvantages, 
suitable polymer characteristics, approaches, applications, 
evaluation, and marketing products of in situ gels. It also focused on 
some reported studies as well as recent advancements of in situ gels. 
The intention of writing this review article to describes every aspect 
of in situ gels, which near the readers a specific feature and might 
contribute to research and development.  
Advantages 
 To decrease the wastage of drug [21] 
 To ease of administration [22] 
 It administered to unconscious and old patients [23] 
 It helps to extended or prolonged release of drugs [24] 
 It allows more patient comfort and compliance [25] 
 Due to the low dose, there will be no drug accumulation and 
minimize the drug toxicity [26] 
 It offers more bio-availability [27] 
 By using natural polymers, provides biocompatibility and 
biodegradation [28]. 
 By using synthetic polymers usually well defined that can be 
modified to yield tolerable degradability and functionality [29] 
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 To Facilitate drug targeting primarily through mucus membranes, 
for non-invasive drug administration [30] 
 It offers a vital stealth characteristic in vivo, owing to its 
hydrophilicity, which increases the in vivo circulation time of the 
delivery device [31] 
 It exhibits bio-adhesiveness to facilitate drug targeting, primarily 
through mucus membranes, for non-invasive drug administration 
[32] 
 To reduce the systemic absorption of drugs drained through the 
nasolacrimal duct [33] 
Disadvantages 
 Requires a high level of fluids [10, 25] 
 The solution form of the drug is more susceptible to degradation 
[34, 35] 
 Due to chemical degradation, there is a chance of stability 
problems [36]  
 Eating and drinking restricted for a few hours after placing the 
drug [25, 36, 37] 
 Only small doses administered [38] 
 Due to low mechanical strength, it may result in premature 
dissolution [36, 39] 
 Particularly for hydrophobic drugs, the quantity and homogeneity 
of drug loading into hydrogels may be limited [39, 40] 
Suitable characteristics of polymers 
An essential ingredient in the manufacture of in situ and preformed 
gel is a polymer. The suitable polymer characteristics for in situ gels 
given below [41-45]: 
 It should be compatible 
 It should not provide any toxic effects 
 It should have good tolerance and optical clarity 
 It should have pseudo-plastic behavior 
 It should be capable of adhering to the mucous membrane 
 It should be capable of decreasing the viscosity with an increase 
in shear rate 
 It should influence tear behavior 
Classification of in situ gelling polymers 
Based on their origin, polymers can be classified or the mechanism 
of gelation. According to a source in situ, gelling systems are 
classified into two types [46-50]. 
i. Natural polymers (e. g., Alginic acid, carrageenan, chitosan, guar gum, 
gellan gum, pectin, sodium hyaluronate, xanthan gum, xyloglucan, etc.) 
ii. Synthetic or semi-synthetic polymers (e. g., CAP, HPMC, MC, PAA, 
PLGA, poloxamers) 
Sol-gel method 
The starting materials, ‘sol’, are usually inorganic metal salts or organic 
compounds such as metal alkoxides. In the conventional ‘sol-gel’ method, 
the precursor goes through reactions of hydrolysis and polymerization 
or condensation to produce a colloidal suspension or solution. Complete 
polymerization along with subsequent loss of solvent directs conversion 
from ‘sol’ (liquid phase) to ‘gel’ (solid phase) [51]. 
Preparation of in situ gel 
The polymer may differ based on the development of in situ gelling 
systems. The polymeric solution was prepared by dispersing required 
quantities of polymers and copolymers in distilled water using a 
magnetic stirrer until the polymers completely dissolve. After the 
preparation of an aqueous drug solution, transferred to a primarily 
prepared polymeric solution with continuous stirring until to get a 
homogeneous solution, and then add excipients based on the delivery 
system. Finally, make up the volume with distilled water [52]. 
Approaches of in situ gels 
There are four generally defined mechanisms used for triggering the 
in situ gel formation of biomaterial [15, 22, 34, 42, 53-55]: 
A. Physiological stimuli (e. g., temperature and pH) 
B. Physical stimuli (e. g., solvent exchange or diffusion and swelling) 
C. Chemical stimuli (e. g., enzymatic, chemical and photo-initiated 
polymerization) 
A. Physiological stimuli 
Based on physiological stimuli classified into two categories [22]: 
Temperature-induced in situ gelling systems or thermally 
triggered systems 
In these systems, no external heat other than body temperature is 
required to cause gelation, and the mechanism showed in fig. 1 [43, 
49]. These are the most widely used systems. 
 
 
Fig. 1: Mechanism involved in temperature triggered system [56] 
 
Three main strategies exist in the engineering of the thermo 
responsive sol-gel polymeric system. For convenience, this thermal-
induced or thermal sensitive in situ gel system classified into three 
types [57-59] 
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i. Negatively thermo-sensitive type; e. g., poly-N-isopropyl 
acrylamide (PNIPAAm)  
ii. Positively thermo-sensitive type, e. g., polyacrylic acid (PAA), poly 
(acrylamide-co-butyl methacrylate), or polyacrylamide 
iii. Thermally reversibly type; e. g. poloxamer, pluronic (poloxamer), 
tetronics (poloxamines), poly (ethylene oxide)-b-poly (propylene 
oxide)-b-poly (ethylene oxide). 
pH triggered systems 
In this approach, pH-responsive or pH-sensitive polymers to be used 
to form a gel. All pH-sensitive polymers contain acidic or alkaline 
ionizable functional groups and that either loose or let accept 
protons in comeback to change in pH. A huge number of ionizable 
groups are known as poly-electrolytes and mechanisms shown in fig. 
2 [49, 60, 61]. 
 
 
Fig. 2: Mechanism involved in the pH-sensitive system [56] 
 
These poly-electrolytes cause an increase in external pH that leads 
to the swelling of hydrogels that leads to the formation of in situ 
gels—some of the anionic groups used as pH triggered systems. E. g., 
Cellulose acetate phthalate (CAP), polyethylene glycol (PEG), pseudo 
latexes, ploy methacrylic acid (PMC), carbomer, and its derivatives, 
etc., Mixtures of poly-methacrylic acid (PMA) and PEG also been 
used as a pH-sensitive system to achieve gelation. The most of 
anionic pH-sensitive polymers are PAA (carbopol, carbomer) or its 
derivatives [22, 62, 63]. 
B. Physical stimuli 
When a material absorbs water from the surrounding environment, 
in situ formation may also occur and expand to the desired space 
[22, 42, 64]. 
Solvent exchange or diffusion 
This process solvent diffuses from the polymer solution into 
surrounding tissue and results in precipitation or solidification of 
the polymer matrix [25, 36]. The most commonly used polymer for 
this approach is N-methyl pyrrolidone (NMP) [65]. 
Swelling 
The polar lipid or polymer swells from inside to outside and slowly 
releases the drug (i.e., to form lyotropic crystalline phase structures). It 
has some bio-adhesive properties and degraded in vivo enzymatic 
action [66]. E. g, Myverol 18-99 (glycerol-mono-oleate) 
C. Chemical reactions 
Chemical reactions that result in situ gelations may involve 
precipitation of inorganic solids by following processes.  
Chemical polymerization of ionic cross-linking 
Ion sensitive polymers induce gelation in the presence of ions like Na+, 
K+, Ca+2, and Mg+2. These ionic polymers undergo a phase transition 
to form a gel. Some of the polysaccharides fall into this class [67, 68]. 
Enzymatic polymerization or enzymatic cross-linking 
In this approach, the gel was formed by cross-linking with the 
enzymes that are present in the body fluids and have some 
advantages over chemical and photochemical methods, and 
mechanism showed in fig. 3 [69, 70]. 
 
 
Fig. 3: Mechanism involved in ion activated system [56] 
 
Photo-initiated polymerization 
It is the most convenient and commonly used approach in the 
formation of in situ gels. Monomers or reactive micromere solutions 
and the initiators injected into a tissue site, and the application of 
electromagnetic radiation used to form a gel. Usually, long-
wavelength ultraviolet (i.e., ketones) and visible (camphor-quinone 
and ethyl eosin) wavelength polymers were used (i.e., acrylates or 
other polymers)—short-wavelength polymers not used because 
they are biologically harmful [71]. 
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Novel approaches of in situ gels 
A variety of unique systems are used to extend the drug delivery by 
in situ gelling systems. These systems delay the elimination of active 
ingredients from the eye and also improved corneal penetration of a 
drug molecule [33, 72]. 
Nanoparticles incorporated in situ gel 
Recently, nanoparticles were employed to address issues related to 
topical formulations. These represent promising drug carriers for 
targeting ocular tissues by remaining at the site of application and 
providing prolonged release by particle degradation or erosion drug 
diffusion or a combination of both [73]. 
Liposome incorporated in situ gel 
It is also a tool for prolonged controlled delivery of a drug; in lipid 
vesicles, active ingredients were encapsulated and transport drug 
through the cornea [74]. 
In situ gelling ocular films or inserts 
Ocular inserts or films are semisolid or solid consistency, usually 
composed of a polymeric vehicle containing the drug, whose size and 
shape are designed for ophthalmic application [75]. 
Nanoemulsified in situ gels 
Nanoemulsions are widely using due to its intrinsic advantages such 
as the higher penetration into the deeper layers, sustained release of 
drugs to the cornea, and ease of sterilization [76]. 
Applications 
Oral drug delivery systems 
Gellan gum, pectin, xyloglucan, etc., are used for oral in situ gels. The 
pH-sensitive gels have potential use in site-specific delivery of drugs 
to specific regions of the gastrointestinal tract (GIT), and some of the 
reported polymers and drugs, including the route of administration 
of in situ gelling systems showed in table 1[12, 74]. 
 
Table 1: Summary of reported drug and polymers of in situ gelling systems 
Drug Polymer used Route of administration Reference 
Doxorubicin Human serum albumin and tartaric acid derivative Parenteral [77] 
Paracetamol and Ambroxo Pectin  Oral [78] 
Pheniramine maleate and albumin FITC Ploymethacrylic acid Parenteral [79] 
Recombinant human interleukin-2 Physically cross-linked dextran Parenteral [80] 
Testosterone Poly-lactic acid and PLGA Parenteral [81] 
Theophylline Gellan gum Oral [82] 
 
Gellan gum 
Gellan gum has the tendency of gelation, which is temperature-
dependent or cations induced. The in situ gelling systems consisted 
of a gellan solution with calcium chloride and sodium citrate 
complexes. When it’s administered orally, the calcium ions were 
released in the acidic environment of the stomach leading to the 
gelation of gellan, thus form an in situ gel [83].  
Pectin 
Gelation of pectin will occur in the presence of H+ions, a source of 
divalent cations; generally, calcium ions are required to produce the 
gels that are suitable as vehicles for drug delivery [22]. The main 
advantage is that it is water-soluble, so there is no need for organic 
solvents in the formulation. Divalent cations present in the stomach 
carry us the transition of pectin to gel state when it is administered 
orally [83]. Calcium ions in the compound form may include in the 
formulation for the induction of pectin gelation. Sodium citrate may 
be added to the above solution to form a complex with most of the 
calcium ions added. The fluid state (‘sol’) is maintained until the 
breakdown of the complex in the acidic environment in the stomach, 
where the release of calcium ions causes gelation [54]. The 
quantities of calcium and citrate ions may be optimized to maintain 
the fluidity. Before administration into the stomach, it is resulting in 
gelation when the formulation. 
Xyloglucan 
Xyloglucan is partially degraded by β-galactosidase, resultant 
product exhibits thermally reversible gelation by the lateral stacking 
of the rod-like chains or on warming to body temperature [84]. 
Depends on the degree of galactose elimination, sol-gel transition 
temperature also varies. Its potential application in oral drug 
delivery exploits the proposed slow gelation time that would allow 
in situ gelations in the stomach following the oral administration of 
chilled xyloglucan solution [83]. The gelation behavior of xyloglucan 
is similar to Pluronic F127, but it forms a ‘gel’ at a much lower 
concentration [22]. 
Ocular drug delivery systems 
Conventional delivery systems often result in reduced bioavailability 
and therapeutic effect because of high tear fluids; dynamics cause 
rapid elimination of drugs [85]. Alginic acid, gellan gum, and 
xyloglucan most commonly used for ocular drug delivery. For locally 
acting drugs such as antimicrobial, anti-inflammatory, and autonomic 
drugs used to relieve intraocular tension in glaucoma [86]. Various 
water-soluble polymers and pH-induced in situ precipitating 
polymeric systems such as carbopol, HPMC, PMA-PEG [87]. 
Alginic acid 
Aqueous solutions of alginates form gels on the addition of di-and 
trivalent metal ions by a cooperative process and involves consecutive 
glucuronic residues in the α-L-glucuronic acid blocks of the alginate 
chain. A prolonged pre-corneal residence of formulations containing 
alginic acid looked for, not only based on its ability to gel in the eye, 
and it includes mucoadhesive properties [22, 83, 88]. 
Carbopol 
It is a well-known pH-dependent, which stays in solution form at 
acidic pH but forms a low viscosity gel at alkaline pH. In combination 
with HPMC, impart the viscosity of carbopol solution while reducing 
the acidity of the solution [22, 83, 89]. 
Gellan gum 
Much of the interest in the pharmaceutical application of gellan gum 
has concentrated on its implementation of ophthalmic drug delivery. 
An aqueous solution of gellan dropped into the eye undergoes a 
transition into the gel state due to the temperature and ionic 
condition (Ca+2) in the tear fluid. Drug release from these in situ gels 
prolonged due to longer pre-corneal contact times of the viscous gels 
compared with conventional eye drops [90, 91].  
Xyloglucan 
Xyloglucan chains are hydrophilic, dense, and having mucoadhesive 
strength, is a suitable candidate for increases in the corneal 
residence time of drugs. The increased drug absorption and the 
prolonged drug elimination were obtained with viscous in situ gel 
formulations [92]. 
Nasal drug delivery systems 
Nasal drug administration has been considered as an alternative route 
for systems use of drugs restricted to intravenous administration. 
Nasal drug delivery can also provide a way of entry to the brain that 
circumvents the blood-brain barrier (BBB) because the olfactory 
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receptor cells are in direct contact with the central nervous system. 
Because of the large absorptive surface and low proteolytic activity, 
the nasal mucosa is considered an attractive site for the delivery of 
vaccines. Nasal vaccines will improve patient compliance and reduce 
production costs compared with parental products. Mostly protein and 
peptides can deliver by this route [93, 94]. 
Parenteral drug delivery systems 
Chitosan is a biocompatible pH-dependent cationic polymer, which 
remains dissolved in an aqueous solution, pH exceeding 6.2 leads to 
form a hydrated gel-like precipitate [22, 83]. The main problem with 
chitosan is its non-biodegradability, and the following procedure 
could overcome this. The pH gelling cationic polysaccharides 
solution is transformed into thermally sensitive pH-dependent, 
without any chemical modification or cross-linking by the addition 
of polyol salts bearing a single anionic head such as glycerol, 
sorbitol, fructose, glucose phosphate salts to chitosan aqueous 
solution [34, 83]. This transformation has solved the non-
biodegradability problem of chitosan. Synthetic polymers are a 
trendy choice for parenteral preparations. The trend in drug 
delivery skills has been towards biodegradable polymers, requiring 
no follow up surgical removal once the drug supply is depleted. 
Aliphatic polyesters such as PLA, PGA, PLCG (poly-lactide-co-
glycolate), PDL (poly-deca-lactone), PCL (poly-ε-caprolactone) have 
been the subject of the most extensive recent investigations and 
various tri-block polymers also used in injectables [95, 96]. The 
feasibility of lactide or glycolide polymers as excipients fort the 
controlled release fo bioactive agents is well proven. These materials 
are subjected to extensive animal and human trials without evidence 
of any harmful side effects. When under GMP conditions from a 
purified monomer, the polymers exhibit no evidence of 
inflammatory response or other adverse effects upon implantation 
[97, 98]. The photoreactions provide rapid polymerization rates at 
physiological temperatures; furthermore, the systems are placed in 
complex-shaped volumes leading to an implant formation. 
Thermosetting systems are in the ‘sol’ form when initially 
constituted, but upon heating, they set into their final shape (‘gel’). 
This sol-gel transition is known as curing [42, 54]. Curing mainly 
involves the formation of covalent cross-links between polymer 
chains to form a macromolecular network. But if this one is heated 
further, it may lead to degradation. In situ precipitating polymeric 
systems, the solution may lead to form a gel, and this precipitation 
induced by a change in temperature (thermosensitive), solvent 
removal, or by a change in pH [22, 83]. A notable example of a 
thermosensitive polymer is NIPAAm, which has a lower critical 
solution temperature phase separation at 32 °C. It is unique 
concerning the sharpness of its almost discontinuous transition, 
which is usually observed only with ionizable polymers. Some tri-
block copolymers like pluronic or poloxamers consist of POE and 
POP units that undergo solubility changes with temperature [99]. 
Dermal and transdermal drug delivery systems 
Skin is considered an essential route of administration of drugs for 
both local and systemic effects. Common preparations for topical 
and dermatological administration of drugs have certain limitations 
like poor adherence, reduced permeability, and compromised 
patient compliance. In vivo studies suggest that 20 % w/w aqueous 
gel maybe it is used as a base for topical administration of the drug. 
The combination of iontophoresis and chemical enhancers results in 
a synergistic enhancement of insulin permeation [100]. 
Rectal drug delivery systems 
Although the oral route is the most convenient route for drug 
administration, this is not possible from either a clinical or 
pharmaceutical perspective. In these cases, the rectal way may 
represent a practical alternative and can be used to administer drugs 
for both local and systemic effects. The environment in the rectum is 
considered relatively constant and stable and has low enzyme 
activity in comparison to other sections of the GIT. However, the 
rectal cavity can be challenged by erratic drug absorption due to the 
low adhesion to the rectal membrane and the potential expulsion of 
the dosage form. These can prevent dosage form leakage, which is 
familiar with rectal suspensions and enemas [33, 101, 102]. 
Vaginal drug delivery systems 
It is a relatively unexploited site other than the treatment of vaginal 
infections, contraception, local menopausal symptoms, and labor 
induction. It is a potential route for a therapeutic portfolio, including 
vaccine delivery and chemotherapy. Blood supply of the vaginal 
epithelium and the large surface area can allow smooth systemic 
drug delivery. Thermoreversible, mucoadhesive gels and pessaries 
studied as formulation platforms for the delivery of antiretroviral 
and antimicrobial compounds, labor-inducing hormones, and even 
for intra-vaginal vaccine delivery [103, 104]. 
Summary of some reported studies by in situ gels showed in table 2, 
and some Marketed products of in situ gelling systems shown in 
table 3. 
Evaluation of in situ gels 
In situ, gels evaluated characterized for the following parameters:  
Physical evaluation 
Compatibility studies 
Compatibility studies carried out for a physical mixture of 
interaction between drug and excipients by a suitable method such 
as Fourier Transform Infra-Red Spectroscopy (FTIR) or Differential 
Scanning Calorimetry (DSC) [105]. 
Appearance 
Preferably, the gels should be transparent. The formulations were 
observed for a general appearance by the naked eye, such as color, 
odor, and the presence of suspended particulate matter [106]. 
Clarity test 
The clarity of the product checked using a black and white 
background [107]. 
pH 
The pH was checked by using a calibrated digital pH meter 
immediately after preparation. In the case of ocular preparations, 
the pH preferably near to ocular pH to avoid eye irritation and 
enhance patient compatibility and tolerance [108]. 
Homogeneity 
By placing the preparation between two glasses, then observe 
particle roughness under the light [109]. 
Isotonicity 
The formulation is mixed with few drops of blood, observe under a 
microscope, and compare with standard ophthalmic preparations. 
For all ophthalmic preparations, maintenance of isotonicity must 
need to prevent tissue damage and irritation to the eye [110]. 
Sol-gel transition temperature 
The temperature of the phase transition of ‘sol’ meniscus was noted 
first and then heated at a specified rate. ‘Gel’ formation is indicated 
by a lack of movement of the meniscus on tilting the tube and note 
down the temperature [22, 83]. 
Gelling time 
Gelling time is the time required for the first detection of gelation, as 
defined in sol-gel transition temperature [111, 112]. 
Texture analysis 
The cohesiveness, consistency, firmness of in situ gels assessed using 
a texture profile analyzer, which mainly indicates the syringe ability 
of ‘sol’ so the formulation can be quickly administration via in vivo 
[113]. 
Spreading coefficient 
The device consists of a ground glass slide fixed on the wooden 
block. Each formulation weighing about 2 grams was placed and 
studied on this ground slide. Gel preparation was then sandwich 
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between this slide and second slide having some dimension as that 
of the fixed glass slide. The second slide was provided with a hook. 
Weight of 1 gram placed on top of the two slides for 5 min. to expel 
air and provide a uniform film of gel between two slides. Measured 
weight is placed on a pan attached to the pulley with the help of a 
hook. The time required by the top slide to separate from a ground 
slide was noted. A shorter interval indicates a better spreading 
coefficient (S) [114, 115]. 
 
M = Weight tied to upper slide 
L = Length of glass slides 
T = time taken to separate the slides 
Gelling strength 
The rheometer determined the gelling strength, and it depends on 
the mechanism of the gelling agent, a specified amount of ‘gel’ 
prepared in a beaker, from the ‘sol’ form. This ‘gel’ containing beaker 
to be raised at a specific rate, so pushing a probe slowly through the 
‘gel’ and the load on the probe is measured by the depth of the 
immersion of the ‘gel’ surface [93, 116]. 
Gelling capacity 
Method 1 
By placing a drop of a freshly prepared formulation with a vial 
containing 2 ml of stimulated tear fluid (STF) and note down the 
time taken for the ‘gel’ formed or ‘gel’ to dissolve in 7.4 pH 
phosphate buffer and its used for determination of the suitable 
polymer concentrations or gelling agent to form in situ gelling 
systems [117]. 
Methods 2 
They were using water-soluble dyes such as amaranth, Congo red, 
indigo blue, etc., used by dissolving 1 g in distilled water and mixed 
with the prepared in situ gel. In vitro, gelling capacities of the 
formulations were measure by placing 5 ml of gelation solution 
(STF) in the glass test tube and maintained the temperature at 
37±0.5 °C. It immediately converted into a stiff gel-like appearance. 
In vitro, gelling capacities are evaluated by the presence of the 
stiffness of the gel. And the time for which the gel converted into 
thick gel remains as such. Further, the color added to give a visual 
appearance to the gel. Based on the three categories in vitro, the 
gelling capacity period was calculated [118]. 
+‘gel’ forms after a few minutes disperse rapidly 
++immediately gelation occurs, remains for a few hours 
+++immediately gelation occurs, remains for an extended period of 
time 
Viscosity and rheology 
At room (i.e., 25 °C) and body temperatures (i.e., 37±0.5 °C), observe 
the viscosity using Brookfield viscometer. Rheology was observed 
due to the thixotropic behavior of the gel. In situ gel preparations 
should show pseudo-plastic and Newtonian flow before and after the 
gelation process. Before and after gelling, it should be 5-1000 m Pas 
(‘sol’) and after 50-50,000 m Pas (‘gel’), respectively. The gel 
formulation in situ should be well-formulated, so administration to 
the patient is proper, especially in ocular administration. However, 
these agents have the disadvantage of making blurred vision and 
leaving residue on the eyelids; due to high viscosity can cause 
difficulties in screening [119, 120]. 
Stability studies 
Stability testing aimed to know the time of storage and the use of the 
material as per the International Conference on Harmonization 
(ICH). Place the sample in a climatic chamber at 40±2 °C 
temperature and 75±5% RH for approximately one month. After a 
few months, the sample analyzed associated clarity, pH, viscosity, 
drug content, rheological, and in vitro dissolution. The storage 
conditions and the length of the study chosen should be sufficient to 
cover the storage, shipment, and subsequent use [121, 122].  
Drug release studies 
In vitro drug release 
In vitro release study of in situ gelling systems can be carried out by 
using Franz diffusion cell to check the duration [44, 123]. 
In vivo drug release 
Evaluation of drug preparation is one drug release in the body (in 
vivo). By knowing the time devastated and the polymer components 




This testing is done with the aseptic transfer technique to avoid 
contamination of the environment. Sterility testing is an essential 
parameter for all ophthalmic preparation, and it must perform for 
aerobic, anaerobic bacteria and fungi by using suitable media under 
aseptic conditions. As per Indian Pharmacopoeia (IP) and British 
Pharmacopoeia (BP), mostly direct inoculation method used to test 
sterility. Initially, inoculate the sample into liquid media 
(thioglycollate medium and soybean digest medium). After that, 
incubate for 7-14 d at different temperatures; for thioglycollate 
medium (30-35 °C) and soybean digest medium (20-25 °C), then 
identify microbial growth [125, 126]. 
Irritation studies 
Albino rabbits are using for the Draize irritation test, a single drop of 
0.04 ml formulation instilled into rabbit eyes (the lower conjunctive 
cul-de-sac). The test eye and by the eyelids can be held together for 
several seconds after installation. Rabbit eyes were observed 
periodically at 1, 24, 48, 72 h, one week after exposure. Ocular 
changes were graded by a scoring system that includes rate any 
alterations to eyelids, conjunctiva, cornea, redness, swelling, 
watering, and iris [127, 128]. 
Antifungal studies 
Initially, sabouraud dextrose dissolves in hot water (i.e., media), 
after 15-20 min. of autoclaving transfer, the organisms such as 
Candida albicans, Aspergillus fumigatus, etc., in media in order and 
put a sample test with a micropipette and let set aside for 30 min. 
After 24 h incubation at 25 °C, the diameter of the zone of inhibition 
or zones was measured, finally compared with positive and negative 
controls [129]. 
Antibacterial studies 
This test was conducted to find out the effectiveness of antibacterial 
of active antibiotic substances, the concentrations that are referred 
to as antibacterial. Finally, the results of the growth of bacteria 
samples could compare with standard antibiotics [130]. 
Statistical evaluation 
Based on obtained data, a multivariate test was used to analyze 
mucoadhesive strength and release studies. To get a significant 
difference by using various SPSS software and considered 
significant at P<0.05. To storage conditions of the test, solutions 
can use one-way analysis variance (ANOVA) of viscosity data using 
prism with significance value (P>0.05). Still, there are no general 
rules regarding this statistical test [131-132]. And some of the 
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Table 2: Summary of some of the marketed products of in situ systems 
Manufacturing company Name of the marketed product Drugs used in the formulation Reference 
Akten Akten TM Lidocaine hydrochloride  [134] 
Alcon Laboratories Inc. Pilopine HS Pilocarpine hydrochloride [135] 
Insite vision Azasite Azithromycin [136] 
Macromed Cytoryn Interleukin-2(IL-2)  [42] 
Macromed Regel Depot Technology Human Growth Hormone [137] 
Merck and Co. Inc Timoptic-XE Timolol maleate [138] 
Spectrum Thea Pharmaceuticals Virgan Ganciclovir [135] 
 
CONCLUSION 
The utilization of in situ gels providing various advantages over 
conventional dosage forms. The use of biocompatible, 
biodegradable, and water-soluble polymers for the in situ gel 
formulation can make excellent and excellent drug delivery systems. 
In recent years researchers have drawn interest, and there is a scope 
to provide an advanced technique in drug delivery. A novel carrier 
can incorporate in these systems to obtain sustained drug delivery 
in a much improved and extreme manner. These systems, as they 
can administer in solution form, undergo gelation at the site of 
action. Finally, in situ, gels are easy to apply and offer patient 
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